Liao, Hanqing
Barra, Carolina http://orcid.org/0000-0002-6836-4906
Zhou, Zhicheng http://orcid.org/0000-0001-9137-7951
Peng, Xu
Woodhouse, Isaac http://orcid.org/0000-0002-8221-7697
Tailor, Arun http://orcid.org/0000-0002-9698-3480
Parker, Robert
Carré, Alexia http://orcid.org/0000-0001-8144-7194
Borrow, Persephone http://orcid.org/0000-0002-3877-9780
Hogan, Michael J. http://orcid.org/0000-0002-6244-2993
Paes, Wayne http://orcid.org/0000-0002-0529-2765
Eisenlohr, Laurence C. http://orcid.org/0000-0002-8475-7910
Mallone, Roberto http://orcid.org/0000-0002-9846-8861
Nielsen, Morten http://orcid.org/0000-0001-7885-4311
Ternette, Nicola http://orcid.org/0000-0002-9283-0743
Funding for this research was provided by:
Leona M. and Harry B. Helmsley Charitable Trust (1901-03689)
European Association for the Study of Diabetes
Cancer Research UK (C6078/A28736)
Wellcome Trust (203141/Z/16/Z)
RCUK | MRC | Medical Research Foundation (MR/K012037)
DH | National Institute for Health Research
Article History
Received: 24 July 2022
Accepted: 14 December 2023
First Online: 22 January 2024
Competing interests
: NT is or has been a paid consultant Roche Pharma, Grey Wolf Therapeutics, T-Cypher Bio, Infinitopes, and Enara Bio. The remaining authors declare no competing interests.